AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05619107 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transauricular nerve stimulation
Description: Protocol as for active but sham ear leads are applied, unable to deliver current.
Study NCT04827836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooled eye drops and povidone-iodine
Description: Cooled oxybuprocaine HCl 0.4% and lidocaine HCl 2% eye drops and cooled povidone-iodine (cul-de-sac 5% povidone-iodine and 10% povidone-iodine).
Study NCT06552559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Combination chemotherapy
Study NCT06310785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: The esketamine group used esketamine as an analgesic during induction and maintenance of anesthesia.
Study NCT06310785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: In the opioid group, sufentanil was used as an analgesic during anesthesia induction and remifentanil was used as an analgesic during anesthesia maintenance.
Study NCT06401174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delivery of patient navigation
Description: Clinics will receive educational materials and access a referral order for patient navigation. Iterative strategies will be used to increase CRC screening
Study NCT06070415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: 12 week- intervention consisting of messages with an explanatory video of each exercise indicating how to do it and how many repetitions to perform
Study NCT06424717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants will be administered Avelumab intravenously (IV).
Study NCT06424717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib
Description: Participants will be administered Tuvusertib orally.
Study NCT06070415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise, usual care
Description: 12 week- intervention. Printed sheets indicating how to exercises and how many repetitions to perform
Study NCT05312086 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: Performing the muscle MRI requires the cooperation of the child in order to remain lying down and motionless throughout the duration of the MRI, about 45 minutes.~Performing MRI does not require the injection of contrast products or radiopharmaceuticals.
Study NCT05536037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Given PO
Study NCT05536037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06070415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home
Study NCT05801302 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foam rolling (shorter volume)
Description: A single intervention will be performed (3 sets of 30 seconds, with between-sets intervals of 30 seconds).
Study NCT05801302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foam rolling (longer volume)
Description: A single intervention will be performed (3 sets of 60 seconds, with between-sets intervals of 30 seconds).
Study NCT06070415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home
Study NCT06656689 — intervention group
Intervention type: PROCEDURE
Intervention: Rezum (water vapor thermal therapy)
Description: Rezum or water vapor thermal therapy is a procedure that involves injecting steam at 103°C into the prostate tissue to induce necrosis and reduce the size of the enlarged prostate.
Study NCT06677268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: Patients will undergo a respiratory rehabilitation program (24 exercise sessions of 90 minutes each, three times a week for 8 weeks and up to 9 therapeutic education workshops of 1 hour of the patient\&#39;s choice)
Study NCT06677294 — intervention group
Intervention type: PROCEDURE
Intervention: Placenta remove
Description: This is an observational study. No intervention was performed
Study NCT06676332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor imagery training
Description: Children in the study group will receive multisensory motor imagery training program 45 minutes. The training protocol consists of several parts that will be run through every training session according to Kumar et al. (2016):~* Watching videos of selected multisensory motor skills for 10 minutes.~* Mental rehearsal of these motor skills 10 minutes.~* Overt practice of the multisensory motor skills for 25 minutes. On the videos, the performance of the skill by a child aged 8-12 years will be shown. All the exercises will be looped to repeat for six to seven times. While projecting the video on the laptop screen, it will be ensured that the children are in a comfortable seating position and the screen is in their visual field. Repetition of the exercises was based on their ability which could be a minimum of five repetitions per session to a maximum of ten repetitions per exercise session.
Study NCT06676332 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: traditional physical therapy
Description: traditional physical therapy training program
Study NCT06676332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy
Description: traditional physical therapy training program
Study NCT05455268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Face-to-face verbal discussions and caregiver training will be provided as deemed necessary by the clinicians.
Study NCT06677333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: This intervention will add 50 g of a whey or pea protein supplement to their usual dietary intake.
Study NCT06677333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea protein
Description: This intervention will add 50 g of a pea protein supplement to their usual dietary intake.
Study NCT05455268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Face-to-face verbal discussions and caregiver training will be provided as deemed necessary by the clinicians.
Study NCT06677528 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire on Aortic Valve Disease, HADS-D, SCL-27, MLHFQ
Study NCT04622787 — intervention group
Intervention type: OTHER
Intervention: Knowledge translation
Description: A. Healthcare Providers Observational Study - measure of the effectiveness of the International Guidelines training courses (face to face and online) delivered to medical professionals (involves all clinical partners).~The International Guidelines training courses on the evidence-based principles of Early Detection (ED), Early surveillance (ES), and Early intervention (EI) will be delivered to healthcare providers.~Face-to-face professional trainings will be set up at each Consortium partner location. E-learning platform will allow for training and follow-up resources will be available to clinicians in all languages that are spoken/written in the locations of the Consortium partners.~Clinicians will be assessed on their knowledge and standard clinical practices in survey format before trainings and after the trainings.
Study NCT06075784 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: reiki
Description: placebo reiki
Study NCT06075784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reiki
Description: placebo reiki
Study NCT06032130 — intervention group
Intervention type: OTHER
Intervention: Clinical measurements
Description: Optometric measurements
Study NCT06032130 — intervention group
Intervention type: OTHER
Intervention: Oculomotor or perceptual therapy
Description: Oculomotor or perceptual visual learning exercices
Study NCT05552404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative therapy
Description: bed rest, fluids, abdominal binder, oral paracetamol, and caffeine
Study NCT05552404 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conservative therapy
Description: bed rest, fluids, abdominal binder, oral paracetamol, and caffeine
Study NCT05552404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: conservative therapy plus Aminophylline (250mg of Aminophylline dissolved in 100ml normal saline for intravenous infusion over 30 minutes)
Study NCT05552404 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trans nasal sphenopalatine ganglion block
Description: conservative therapy plus sphenopalatine ganglion block SPGB using hollow cotton swab and lidocaine 2%
Study NCT05757687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omega device
Description: The ProArc Medical Omega system is a prostatic reshaping device. The Omega System is comprised of two main components: Omega Delivery Device and Omega Implant.~The delivery system uses a diathermy electrode to perform a circular and superficial incision through the urethral wall into the prostate tissue, into which the arc-shaped permanent implant is placed. The implant is made up of commonly used surgical implantable nitinol material, coated with Parylene coating. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra.
Study NCT05821322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity trial intervention
Description: 60 minutes aerobic ergocyle exercice at 60% VO2 Peak
Study NCT05821322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity trial intervention
Description: 60 minutes aerobic ergocyle exercice at 60% VO2 Peak
Study NCT05954832 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography and Clearsight BP measurements before, immediately after anesthesia induction and after intubation (for 20 min)
Study NCT05592353 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brace
Description: Brace following hip arthroscopy
Study NCT06094998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: hemogram examination
Description: It will be studied hemogram examination, immunity indicators (cellular components CD3, CD4, CD8, CD16, CD20, CD25, CD95, CD3 HLA DR+, CD# HLA-DR; humoral components - IgM, IgA, IgE, IgG) and laboratory investigations in endocrine system (TSH, free T3 and T4 levels, insulin, insulin-like growth factor-1 (IGF-1), somatotropic hormone (STH); glucose, potassium, sodium) in 120 children born after ART. Researchers will compare 132 children conceived spontaneously to see if ART can influent on the health status in future.
Study NCT03070691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225B
Description: Cream, 2x daily
Study NCT03070691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: cream, 2x daily
Study NCT05666518 — intervention group
Intervention type: DRUG
Intervention: Vericiguat (Verquvo, BAY1021189)
Description: Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
Study NCT05666518 — intervention group
Intervention type: DRUG
Intervention: Standard of care
Description: Dosage at the discretion of the treating physician
Study NCT05814497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory Task
Description: Reversing checkerboard, tones, and finger opposition.
Study NCT05814497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graphesthesia
Description: Trace numbers on skin.
Study NCT05814497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Divided attention
Description: Divide attention between two noxious stimuli.
Study NCT04646187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Dosing interval lengthening from 8 to 12 weeks
Study NCT04646187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Dosing interval lengthening from 2 to 3 weeks
Study NCT05923684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NLP-based Feedback
Description: Audio recordings will be made using either digital recorders or telehealth platform-generated transcripts. Patient reports will include only the extracted sentences related to content areas. Physician reports will note the extracted statements across each content area, the quality scores for individual statements based on the pre-specified hierarchy, the statements that achieved the highest score across each content area, and feedback on what could be improved. For patients, decisional conflict and risk perception will be assessed before and after receiving the NLP-based feedback. For physicians, the investigators will assess baseline quality of risk communication by pre-specified hierarchy, any changes in individual physician communication over time, and accuracy of risk estimates for key content areas.
Study NCT06104345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral typhoid fever vaccine
Description: Oral typhoid fever vaccine (Vivotif®) on Days 0, 2 and 4.
Study NCT06104345 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral typhoid fever vaccine
Description: Oral typhoid fever vaccine (Vivotif®) on Days 0, 2 and 4.
Study NCT06104345 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral cholera vaccine
Description: Oral cholera vaccine (Dukoral®) on Days 0 and 7.
Study NCT06104345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine
Description: Oral cholera vaccine (Dukoral®) on Days 0 and 7.
Study NCT04840511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine group
Description: lidocaine 1.5 mg/kg bolus (infused over 10 min) followed by 2.0 mg/kg/h during operation and 1.0 mg/kg/h during postoperative 24 hours (no more than 120 mg/h)
Study NCT04840511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: normal saline 0.15 ml bolus followed by 0.2 ml/kg/hr during operation and 0.1 ml/kg/hr during postoperative 24 hours
Study NCT06140693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous exercise at an intensity below the ventilatory threshold
Description: 30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 80% of the intensity at the ventilatory threshold
Study NCT05364671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raphamin
Description: Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. On the first day, 8 tablets should be administered using the following regimen: 1 tablet every 30 minutes in the first 2 hours (5 tablets in total within 2 hours), then additionally one tablet 3 times with regular time intervals. From day 2 onwards, 1 tablet taken 3 times daily. The treatment period is 5 days.
Study NCT05364671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. Placebo is administered according to the Raphamin regimen.
Study NCT05586308 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text-massaging suport
Description: Text-messaging quitting support program (i.e., This is Quitting) is an evidence-based, free mobile program from Truth Initiative designed to help young people quit vaping. The program is fully automated and interactive. To establish or reinforce perceived social norms and social support around quitting, a majority of messages come from other users who have submitted them to the program.
Study NCT05586308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-massaging suport
Description: Text-messaging quitting support program (i.e., This is Quitting) is an evidence-based, free mobile program from Truth Initiative designed to help young people quit vaping. The program is fully automated and interactive. To establish or reinforce perceived social norms and social support around quitting, a majority of messages come from other users who have submitted them to the program.
Study NCT05586308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text-massaging suport
Description: Text-messaging quitting support program (i.e., This is Quitting) is an evidence-based, free mobile program from Truth Initiative designed to help young people quit vaping. The program is fully automated and interactive. To establish or reinforce perceived social norms and social support around quitting, a majority of messages come from other users who have submitted them to the program.
Study NCT05586308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: 1. Participants will earn $3 for each saliva cotinine sample submission regardless of positive or negative results after the quit day (an assessments at Week 6, Week 8, Week 10, and Week 12, during the abstinence phase)~2. Participants will earn additional escalating rewards for each negative sample- $7 for Week 6, $12 for Week 8, $17 for Week 10, and $22 for Week 12 (2 months after the target quit date). The bonus starts at $7 and increase by $5 for each subsequent negative cotinine sample (i.e., $7, $12, $17, and $22).~3. A reset contingency will be used. That is the reward amount will be returned back to original $7 if there is a missing or positive saliva cotinine sample
Study NCT05586308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial incentive
Description: 1. Participants will earn $3 for each saliva cotinine sample submission regardless of positive or negative results after the quit day (an assessments at Week 6, Week 8, Week 10, and Week 12, during the abstinence phase)~2. Participants will earn additional escalating rewards for each negative sample- $7 for Week 6, $12 for Week 8, $17 for Week 10, and $22 for Week 12 (2 months after the target quit date). The bonus starts at $7 and increase by $5 for each subsequent negative cotinine sample (i.e., $7, $12, $17, and $22).~3. A reset contingency will be used. That is the reward amount will be returned back to original $7 if there is a missing or positive saliva cotinine sample
Study NCT05586308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media literacy
Description: Media literacy e-learning lessons cover topics regarding what e-cigarettes are and how they work, how nicotine and nicotine addiction affects the brain and behavior, how to prepare to quit vaping, developing a quit plan and how to deal with cravings and relapse. The program focuses on changing knowledge, attitudes and beliefs related to e-cigarette use, as well as emphasizing vaping related media literacy.
Study NCT05586308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Media literacy
Description: Media literacy e-learning lessons cover topics regarding what e-cigarettes are and how they work, how nicotine and nicotine addiction affects the brain and behavior, how to prepare to quit vaping, developing a quit plan and how to deal with cravings and relapse. The program focuses on changing knowledge, attitudes and beliefs related to e-cigarette use, as well as emphasizing vaping related media literacy.
Study NCT05420324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH003
Description: YH003 will be administered intravenously over 30 minutes every 21-day cycle.
Study NCT05420324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
Study NCT05420324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin paclitaxel
Description: Albumin paclitaxel will be administered intravenously over 30 minutes every 21-day cycle.
Study NCT05650086 — intervention group
Intervention type: DEVICE
Intervention: Thermalytix
Description: One-time Thermal imaging is performed for this cohort.
Study NCT06140693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous exercise at an intensity at the ventilatory threshold
Description: 30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 100% of the intensity at the ventilatory threshold
Study NCT06140693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous exercise at an intensity above the ventilatory threshold
Description: 30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 110% of the intensity at the ventilatory threshold
Study NCT05169697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A:YH002+YH001
Description: YH002 on CnD1,YH001 on CnD8,Q3W
Study NCT05169697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B:YH002+YH001
Description: YH002 and YH001 on same day,Q3W
Study NCT05169697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH002+YH001
Description: A traditional 3+3 dose escalation algorithm
Study NCT05794022 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: 1 MRI at 1 month with gadolinium injection
Study NCT06140693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sprint interval training
Description: 22 min of cycling exercise on a stationary bike with a warm-up at a resistance of 25 W, followed by four 30-s 'all-out' sprints, each with a 4-min recovery intervals at 25 W
Study NCT06140693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced-exertion high-intensity interval training
Description: 10 min of cycling exercise on a stationary bike with a warm-up at a resistance of 25 W, followed by two 20-s 'all-out' sprints, with a 3-min and a 4-min recovery interval at 25 W after the first and second sprint respectively